Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nu-Med PlusNUMD Debt-to-EBITDA is -4.29 as of Mar. 2026. The stock has 1 warning sign investors should review. Among 467 Medical Devices & Instruments companies, Nu-Med Plus ranks worse than 214132.55% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Nu-Med Plus's Debt-to-EBITDA or its related term are showing as below:
NUMD'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.19 Med: -0.22 Max: 0.07
Current: -5.19
During the past 13 years, the highest Debt-to-EBITDA Ratio of Nu-Med Plus was 0.07. The lowest was -5.19. And the median was -0.22.
NUMD's Debt-to-EBITDA is ranked worse than 100% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs NUMD: -5.19
Nu-Med Plus (OTCPK:NUMD) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Nu-Med Plus Debt-to-EBITDA Related Terms
Nu-Med Plus Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Nu-Med Plus's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NUMD vs SSKN, ODYY, NUWE: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Nu-Med Plus's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nu-Med Plus Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nu-Med Plus's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nu-Med Plus's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Nu-Med Plus (NUMD) has a Debt-to-EBITDA of -4.29 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nu-Med Plus. According to the industry distribution chart, Nu-Med Plus ranks #999999 out of 467 companies in the Medical Devices & Instruments industry.
Is Nu-Med Plus' Debt-to-EBITDA too high?
Nu-Med Plus' current Debt-to-EBITDA is -4.29. Based on the distribution chart, Nu-Med Plus ranks #999999 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Nu-Med Plus' Debt-to-EBITDA compare to SSKN and ODYY?
According to the Medical Devices & Instruments industry distribution chart, Nu-Med Plus ranks #999999 out of 467 companies for Debt-to-EBITDA. This places Nu-Med Plus in the lower half of its industry. The industry median Debt-to-EBITDA is 1.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nu-Med Plus. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nu-Med Plus's current Debt-to-EBITDA is -4.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nu-Med Plus stock overvalued right now?
Nu-Med Plus (NUMD) has a current Debt-to-EBITDA of -4.29. The current Debt-to-EBITDA is -4.29. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Nu-Med Plus (NUMD), the current Debt-to-EBITDA is -4.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nu-Med Plus Inc is a medical device company engaged in the design, innovation, development, enhancement, and commercialization of beginning, early, and selective later-stage quality medical devices. It focuses on the formulation of Nitric Oxide powder, which is a desktop generator device which delivers inhaled Nitric Oxide to replace expensive pressurized canisters and a mobile rechargeable device to deliver inhaled Nitric Oxide gas to offer solutions to hospitals, health systems, and the medical community throughout the world. It is currently working to locate a merger partner that will be able to fund the final development of these products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NUMD has been successfully added to your 
